Clinic Roundup

Keryx Biopharmaceuticals Inc., of New York, and Aeterna Zentaris Inc., of Quebec City, completed enrollment in the pivotal Phase III trial of PI3K/Akt inhibitor perifosine (KRX-0401) plus Xeloda (capecitabine, Roche AG) for colorectal cancer.